A drug therapy currently used to treat non-Hodgkin’s lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical trial. Because the drug targets the immune system’s B-cells, rather than the immune system’s traditionally targeted T-cells — long considered the primary culprit — the finding provides a new insight into the cause of the disease, the researchers say.